Heart failure & cardiomyopathies
Geographic variations in the PARADIGM-HF heart failure trial
Authors' conclusion
There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan.
Study context
- Population
- Patients with heart failure (HF) in PARADIGM-HF, by region
- Participants
- 602 / 1,680 / 2,762 / 1,433 / 1,487
- Comparison
- Geographic regions
- North America (NA)n = 602reference
- Western Europe (WE)n = 1,680
- Central/Eastern Europe/Russia (CEER)n = 2,762
- Latin America (LA)n = 1,433
- Asia-Pacific (AP)n = 1,487
- Primary endpoint
- CV death or HF hospitalization (per 100 patient-years)
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
CV death or HF hospitalization rate
Further findings
| Outcome | Values |
|---|---|
| Mean age | NA 65 years · WE mean 68 years · LA 63 years · AP 58 years |
| Defibrillating device | NA 54 % · AP 2% |
| MRA prescribed | NA 36 % · LA 65% |
Adjusted risk vs NA
- Cardiovascular (CV) death risk higher in LA and AP; HF hospitalization risk lower in WE
- After adjustment for prognostic variables
Sacubitril/valsartan benefit by region
- Benefit of sacubitril/valsartan consistent across regions
Original publication
Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. Published 28 June 2016. doi:10.
Summarised from the published abstract; every number is checked against it